The resulting fusion gene BCR-ABL1 gives rise to the BCR-ABL fusion protein and is disease defining for CML with proliferative and survival advantage of the cell (Quintás-Cardama and Cortes, 2009). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.